Featured Editorial

  1. Rethinking The Oligonucleotide Backbone: Why RNA Therapeutics May Need A New Molecular Design Framework 6/24/2026

    New backbone chemistries could unlock greater control over delivery, specificity, and safety, expanding the molecular design space for RNA medicines.

  2. RNA Platforms: What Transfers And What Breaks 6/23/2026

    A practical framework for distinguishing reusable RNA platform knowledge from biology-specific unknowns as therapeutics expand into new tissues and indications.

  3. Stay "Stereocurious": What The Future Holds For Oligo Quality 6/22/2026

    Overall, there were two areas of discussion at TIDES that demonstrate the amount of growth we have yet to do as a space — particularly in the realms of regulatory development and quality. As I intend to showcase here in part 1 of this muti-part article, this year’s TIDES was a great reflection of the tension(s) that can arise as we realize how much space exists between where we are and where we’re going next. 

  4. The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of Therapeutics 6/19/2026

    Long non-coding RNAs and splicing networks are emerging as master regulators of cellular identity, opening new therapeutic opportunities beyond proteins.

  5. RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease Biology 6/18/2026

    RNA-binding proteins orchestrate splicing, stability, localization, and translation, emerging as powerful regulators and therapeutic targets in disease.

  6. Targeting The Uncharted Heart: Why The Next Era Of siRNA Belongs In Cardiology 6/15/2026

    During our conversation, Gallagher walked me through what’s keeping her up at night as she leads the company and its first siRNA candidate toward an IND, elaborating on the role RNA can play in cardiomyopathies and identifying the unique challenges of developing RNA medicines today.

  7. Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi Therapeutics 6/8/2026

    As siRNA design matures, the next breakthroughs will depend on balancing chemical optimization, delivery challenges, and expanding beyond established design rules.

  8. Beyond The Liver: How Machine Learning-Optimized LNPs Are Expanding RNA Delivery Into Adipose Tissue 6/8/2026

    Machine learning-guided LNP design is enabling targeted RNA delivery to adipose tissue, opening new possibilities for obesity, metabolic disease, and beyond.

  9. Following The Data To The Heart: Atrium's Quest For Next-Gen Targeted RNA Delivery 6/8/2026

    In this two-part series, Gallagher shares more about her goals for Atrium following its spin-out from Novartis, articulating what it looks like and means to “pave a path” to greater patient access in rare cardiomyopathies. Here in part one, we start with a look into the formation of Atrium, sharing the “why” behind the company’s formation and what’s next for the company’s targeted delivery platform. 

  10. Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2) 6/4/2026

    Part 2 explores the downstream technologies that turn RNA into a therapeutic product, from impurity removal and LNP formulation to GMP infrastructure and scalable manufacturing.